Global Hepatitis C Drugs Market Information, By Drug Class (Anti-Viral, Immuno-modulators and others), By Medicine System (Allopathic, Alternative and Others), By Route of Administration (Oral, Injectable and others) and By End User (Hospitals and Private) – Forecast Till 2022
Taking into consideration all factors the market for global hepatitis drugs was estimated to rise from $18700 million to $22721.1 million by the end of forecasting period reflecting a sluggish CAGR of 3.3%.
KEY PLAYERS FOR GLOBAL HEPATITIS C DRUGS MARKET:
Gilead sciences Inc., Abbvie Inc, Johnson & Johnson, Merck & co. Inc., Glaxosmithkline plc, Novartis AG, Bristol-Myers Squibb, Hoffmann-la Roche ltd. and others.
Get PDF Sample of This Report @ https://www.marketresearchfuture.com/sample_request/2487 .
REGIONAL ANALYSIS FOR HEPATITIS C DRUGS MARKET
Globally America is the largest market for Hepatitis C drugs. Europe is the second-largest market for Hepatitis C drugs. The developed regions market is expected to remain stagnant and even may show negative CAGR due to falling patient’s number. Thus market of developing nations however will show moderate growth and is expected to catch on the developed regions. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global hepatitis C market.
SEGMENTS FOR HEPATITIS C DRUGS MARKET
Global hepatitis c drugs market has been segmented on the basis of drug class which comprises anti-viral, immuno-modulators and others. On the basis of medicine system; market is segmented into allopathic, alternative and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of end user the market is segmented into hospitals and private.
MARKET SYNOPSIS FOR HEPATITIS C DRUGS MARKET
Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay colored stools etc.
Hepatitis is caused by a variety of factors both microbial and non-microbial. However hepatitis C is caused by hepatitis C virus and affects between 130–150 million people globally every year of which approximately 700 000 people die from hepatitis C-related liver diseases. What is of greater concern is the fact that 15 to 20% of chronically infected patients develop liver cirrhosis or liver cancer.
The market for hepatitis C is driven by factors such as disease prevalence, rise in government subsidy and reimbursement especially in U.S., greater screening especially in developing nations, drug abuse and unsafe sex etc.
However the restraints are overwhelming such as self-imitating nature of the disease in a sizable number of patients, challenge of herbal treatment offered at negligible prices especially in developing regions, price war between companies such as between Gilead and Merck, rising urbanization and better sanitation etc. Thus the market in developed regions appears to reach a plateau as the number of people affected is not rising in developed regions. The reevaluation of hepatitis C strategy by companies such as Boehringer Ingelheim and its decision to refrain from moving forward in hepatitis C research also is an indication of stagnancy in developed region markets.
Get Discount on This Premium Report@ https://www.marketresearchfuture.com/check-discount/2487 .
MAJOR TOC FOR HEPATITIS C DRUGS MARKET
CHAPTER 1. INTRODUCTION
1.1 Definition
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure
CHAPTER 2. RESEARCH METHODOLOGY
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
CHAPTER 3. MARKET DYNAMICS
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
CHAPTER 4. MARKET FACTOR ANALYSIS
4.1 Porter’s Five Forces Model
4.1.1 Bargaining Power of Suppliers
4.1.2 Bargaining Power of Customer
4.1.3 Intensity Of Competitor’s
4.1.4 Threat of New Entrants
LIST OF TABLES
TABLE 1 GLOBAL HEPATITIS C DRUGS MARKET, 2013-2022 (USD MILLION)
TABLE 2 GLOBAL HEPATITIS C DRUGS MARKET, BY DRUG CLASS, 2013-2022 (USD MILLION)
TABLE 3 GLOBAL HEPATITIS C DRUGS MARKET, BY MEDICINE SYSTEM, 2013-2022 (USD MILLION)
TABLE 4 GLOBAL HEPATITIS C DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2013-2022 (USD MILLION)
TABLE 5 GLOBAL HEPATITIS C DRUGS MARKET, BY END USER, 2013-2022 (USD MILLION)
TABLE 6 GLOBAL HEPATITIS C DRUGS MARKET, BY REGION, 2013-2022 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 PORTERS FIVE FORCES MODEL
FIGURE 3 GLOBAL HEPATITIS C DRUGS MARKET, BY DRUG CLASS
FIGURE 4 GLOBAL HEPATITIS C DRUGS MARKET, BY MEDICINE SYSTEM
FIGURE 5 GLOBAL HEPATITIS C DRUGS MARKET, BY ROUTE OF ADMINISTRATION
FIGURE 6 GLOBAL HEPATITIS C DRUGS MARKET, BY END USER
FIGURE 7 GLOBAL HEPATITIS C DRUGS MARKET, BY REGION
FIGURE 8 GLOBAL HEPATITIS C DRUGS MARKET: COMPANY SHARE ANALYSIS, 2015 (%)
TOC CONTINUED….
Ask to Expert Inquire @https://www.marketresearchfuture.com/enquiry/2487 .
About Us:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/hepatitis-c-drugs-market-2487